Report Detail

Request for Sample of this report

Other Global Anti-CD34 Antibody Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4679798
    • |
  • 26 February, 2026
    • |
  • Global
    • |
  • 137 Pages
    • |
  • GIR
    • |
  • Other

According to our (Global Info Research) latest study, the global Anti-CD34 Antibody market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Anti-CD34 Antibody is an antibody that targets CD34, a cell surface protein expressed on hematopoietic stem cells, endothelial progenitor cells, and other cell types. It is commonly used in research to study the role of CD34 in hematopoiesis, angiogenesis, and tumorigenesis. The antibody is also used in clinical applications, such as stem cell transplantation and the diagnosis of certain diseases, including types of cancer and bone marrow disorders.
The industry trend for Anti-CD34 Antibody has experienced significant growth in recent years, driven by its essential role in stem cell research and its potential applications in regenerative medicine. The antibody"s ability to isolate and characterize hematopoietic stem cells has made it a crucial tool for researchers and clinicians. Additionally, the use of Anti-CD34 Antibody in the development of targeted therapies and diagnostic tests for diseases involving CD34 expression, such as leukemia and lymphoma, continues to fuel its demand. As the field of personalized medicine progresses, the utility of Anti-CD34 Antibody in patient diagnosis and treatment is expected to further propel its industry trend.
This report is a detailed and comprehensive analysis for global Anti-CD34 Antibody market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Anti-CD34 Antibody market size and forecasts, in consumption value ($ Million), 2021-2032
Global Anti-CD34 Antibody market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Anti-CD34 Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Anti-CD34 Antibody market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-CD34 Antibody
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-CD34 Antibody market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BosterBio, ProSci, GeneTex, Biomatik, MyBioSource, Synaptic Systems, Signalway Antibody, Thermo Fisher Scientific, Biorbyt, NSJ Bioreagents, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Anti-CD34 Antibody market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal Antibody
Polyclonal Antibody
Market segment by Application
Biotechnology
Medical
University
Others
Market segment by players, this report covers
BosterBio
ProSci
GeneTex
Biomatik
MyBioSource
Synaptic Systems
Signalway Antibody
Thermo Fisher Scientific
Biorbyt
NSJ Bioreagents
R&D Systems
Novus Biologicals
LSBio
Abnova Corporation
Bioss
EpiGentek
Wuhan Fine Biotech
BioLegend
StressMarq Biosciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Anti-CD34 Antibody product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Anti-CD34 Antibody, with revenue, gross margin, and global market share of Anti-CD34 Antibody from 2021 to 2026.
Chapter 3, the Anti-CD34 Antibody competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Anti-CD34 Antibody market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Anti-CD34 Antibody.
Chapter 13, to describe Anti-CD34 Antibody research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Anti-CD34 Antibody by Type
    • 1.3.1 Overview: Global Anti-CD34 Antibody Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Anti-CD34 Antibody Consumption Value Market Share by Type in 2025
    • 1.3.3 Monoclonal Antibody
    • 1.3.4 Polyclonal Antibody
  • 1.4 Global Anti-CD34 Antibody Market by Application
    • 1.4.1 Overview: Global Anti-CD34 Antibody Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Biotechnology
    • 1.4.3 Medical
    • 1.4.4 University
    • 1.4.5 Others
  • 1.5 Global Anti-CD34 Antibody Market Size & Forecast
  • 1.6 Global Anti-CD34 Antibody Market Size and Forecast by Region
    • 1.6.1 Global Anti-CD34 Antibody Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Anti-CD34 Antibody Market Size by Region, (2021-2032)
    • 1.6.3 North America Anti-CD34 Antibody Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Anti-CD34 Antibody Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Anti-CD34 Antibody Market Size and Prospect (2021-2032)
    • 1.6.6 South America Anti-CD34 Antibody Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Anti-CD34 Antibody Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 BosterBio
    • 2.1.1 BosterBio Details
    • 2.1.2 BosterBio Major Business
    • 2.1.3 BosterBio Anti-CD34 Antibody Product and Solutions
    • 2.1.4 BosterBio Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 BosterBio Recent Developments and Future Plans
  • 2.2 ProSci
    • 2.2.1 ProSci Details
    • 2.2.2 ProSci Major Business
    • 2.2.3 ProSci Anti-CD34 Antibody Product and Solutions
    • 2.2.4 ProSci Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 ProSci Recent Developments and Future Plans
  • 2.3 GeneTex
    • 2.3.1 GeneTex Details
    • 2.3.2 GeneTex Major Business
    • 2.3.3 GeneTex Anti-CD34 Antibody Product and Solutions
    • 2.3.4 GeneTex Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 GeneTex Recent Developments and Future Plans
  • 2.4 Biomatik
    • 2.4.1 Biomatik Details
    • 2.4.2 Biomatik Major Business
    • 2.4.3 Biomatik Anti-CD34 Antibody Product and Solutions
    • 2.4.4 Biomatik Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Biomatik Recent Developments and Future Plans
  • 2.5 MyBioSource
    • 2.5.1 MyBioSource Details
    • 2.5.2 MyBioSource Major Business
    • 2.5.3 MyBioSource Anti-CD34 Antibody Product and Solutions
    • 2.5.4 MyBioSource Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 MyBioSource Recent Developments and Future Plans
  • 2.6 Synaptic Systems
    • 2.6.1 Synaptic Systems Details
    • 2.6.2 Synaptic Systems Major Business
    • 2.6.3 Synaptic Systems Anti-CD34 Antibody Product and Solutions
    • 2.6.4 Synaptic Systems Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Synaptic Systems Recent Developments and Future Plans
  • 2.7 Signalway Antibody
    • 2.7.1 Signalway Antibody Details
    • 2.7.2 Signalway Antibody Major Business
    • 2.7.3 Signalway Antibody Anti-CD34 Antibody Product and Solutions
    • 2.7.4 Signalway Antibody Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Signalway Antibody Recent Developments and Future Plans
  • 2.8 Thermo Fisher Scientific
    • 2.8.1 Thermo Fisher Scientific Details
    • 2.8.2 Thermo Fisher Scientific Major Business
    • 2.8.3 Thermo Fisher Scientific Anti-CD34 Antibody Product and Solutions
    • 2.8.4 Thermo Fisher Scientific Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.9 Biorbyt
    • 2.9.1 Biorbyt Details
    • 2.9.2 Biorbyt Major Business
    • 2.9.3 Biorbyt Anti-CD34 Antibody Product and Solutions
    • 2.9.4 Biorbyt Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Biorbyt Recent Developments and Future Plans
  • 2.10 NSJ Bioreagents
    • 2.10.1 NSJ Bioreagents Details
    • 2.10.2 NSJ Bioreagents Major Business
    • 2.10.3 NSJ Bioreagents Anti-CD34 Antibody Product and Solutions
    • 2.10.4 NSJ Bioreagents Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 NSJ Bioreagents Recent Developments and Future Plans
  • 2.11 R&D Systems
    • 2.11.1 R&D Systems Details
    • 2.11.2 R&D Systems Major Business
    • 2.11.3 R&D Systems Anti-CD34 Antibody Product and Solutions
    • 2.11.4 R&D Systems Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 R&D Systems Recent Developments and Future Plans
  • 2.12 Novus Biologicals
    • 2.12.1 Novus Biologicals Details
    • 2.12.2 Novus Biologicals Major Business
    • 2.12.3 Novus Biologicals Anti-CD34 Antibody Product and Solutions
    • 2.12.4 Novus Biologicals Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Novus Biologicals Recent Developments and Future Plans
  • 2.13 LSBio
    • 2.13.1 LSBio Details
    • 2.13.2 LSBio Major Business
    • 2.13.3 LSBio Anti-CD34 Antibody Product and Solutions
    • 2.13.4 LSBio Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 LSBio Recent Developments and Future Plans
  • 2.14 Abnova Corporation
    • 2.14.1 Abnova Corporation Details
    • 2.14.2 Abnova Corporation Major Business
    • 2.14.3 Abnova Corporation Anti-CD34 Antibody Product and Solutions
    • 2.14.4 Abnova Corporation Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Abnova Corporation Recent Developments and Future Plans
  • 2.15 Bioss
    • 2.15.1 Bioss Details
    • 2.15.2 Bioss Major Business
    • 2.15.3 Bioss Anti-CD34 Antibody Product and Solutions
    • 2.15.4 Bioss Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Bioss Recent Developments and Future Plans
  • 2.16 EpiGentek
    • 2.16.1 EpiGentek Details
    • 2.16.2 EpiGentek Major Business
    • 2.16.3 EpiGentek Anti-CD34 Antibody Product and Solutions
    • 2.16.4 EpiGentek Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 EpiGentek Recent Developments and Future Plans
  • 2.17 Wuhan Fine Biotech
    • 2.17.1 Wuhan Fine Biotech Details
    • 2.17.2 Wuhan Fine Biotech Major Business
    • 2.17.3 Wuhan Fine Biotech Anti-CD34 Antibody Product and Solutions
    • 2.17.4 Wuhan Fine Biotech Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Wuhan Fine Biotech Recent Developments and Future Plans
  • 2.18 BioLegend
    • 2.18.1 BioLegend Details
    • 2.18.2 BioLegend Major Business
    • 2.18.3 BioLegend Anti-CD34 Antibody Product and Solutions
    • 2.18.4 BioLegend Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 BioLegend Recent Developments and Future Plans
  • 2.19 StressMarq Biosciences
    • 2.19.1 StressMarq Biosciences Details
    • 2.19.2 StressMarq Biosciences Major Business
    • 2.19.3 StressMarq Biosciences Anti-CD34 Antibody Product and Solutions
    • 2.19.4 StressMarq Biosciences Anti-CD34 Antibody Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 StressMarq Biosciences Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Anti-CD34 Antibody Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Anti-CD34 Antibody by Company Revenue
    • 3.2.2 Top 3 Anti-CD34 Antibody Players Market Share in 2025
    • 3.2.3 Top 6 Anti-CD34 Antibody Players Market Share in 2025
  • 3.3 Anti-CD34 Antibody Market: Overall Company Footprint Analysis
    • 3.3.1 Anti-CD34 Antibody Market: Region Footprint
    • 3.3.2 Anti-CD34 Antibody Market: Company Product Type Footprint
    • 3.3.3 Anti-CD34 Antibody Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Anti-CD34 Antibody Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Anti-CD34 Antibody Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Anti-CD34 Antibody Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Anti-CD34 Antibody Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Anti-CD34 Antibody Consumption Value by Type (2021-2032)
  • 6.2 North America Anti-CD34 Antibody Market Size by Application (2021-2032)
  • 6.3 North America Anti-CD34 Antibody Market Size by Country
    • 6.3.1 North America Anti-CD34 Antibody Consumption Value by Country (2021-2032)
    • 6.3.2 United States Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Anti-CD34 Antibody Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Anti-CD34 Antibody Consumption Value by Type (2021-2032)
  • 7.2 Europe Anti-CD34 Antibody Consumption Value by Application (2021-2032)
  • 7.3 Europe Anti-CD34 Antibody Market Size by Country
    • 7.3.1 Europe Anti-CD34 Antibody Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 7.3.3 France Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Anti-CD34 Antibody Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Anti-CD34 Antibody Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Anti-CD34 Antibody Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Anti-CD34 Antibody Market Size by Region
    • 8.3.1 Asia-Pacific Anti-CD34 Antibody Consumption Value by Region (2021-2032)
    • 8.3.2 China Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 8.3.5 India Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Anti-CD34 Antibody Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Anti-CD34 Antibody Consumption Value by Type (2021-2032)
  • 9.2 South America Anti-CD34 Antibody Consumption Value by Application (2021-2032)
  • 9.3 South America Anti-CD34 Antibody Market Size by Country
    • 9.3.1 South America Anti-CD34 Antibody Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Anti-CD34 Antibody Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Anti-CD34 Antibody Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Anti-CD34 Antibody Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Anti-CD34 Antibody Market Size by Country
    • 10.3.1 Middle East & Africa Anti-CD34 Antibody Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Anti-CD34 Antibody Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Anti-CD34 Antibody Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Anti-CD34 Antibody Market Drivers
  • 11.2 Anti-CD34 Antibody Market Restraints
  • 11.3 Anti-CD34 Antibody Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Anti-CD34 Antibody Industry Chain
  • 12.2 Anti-CD34 Antibody Upstream Analysis
  • 12.3 Anti-CD34 Antibody Midstream Analysis
  • 12.4 Anti-CD34 Antibody Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Anti-CD34 Antibody. Industry analysis & Market Report on Anti-CD34 Antibody is a syndicated market report, published as Global Anti-CD34 Antibody Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Anti-CD34 Antibody market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo